Weekly insulin efsitora alfa is non-inferior to daily insulin degludec for reducing HbA1c in type 1 diabetes
1. Once weekly efsitora demonstrated non-inferiority compared with degludec with regards to change in HbA1c. 2. Patients in the efsitora ...
1. Once weekly efsitora demonstrated non-inferiority compared with degludec with regards to change in HbA1c. 2. Patients in the efsitora ...
1. Machine learning (ML) models developed by Lehmann and colleagues used driving characteristics and head motion data to detect hypoglycemic ...
1. Aflibercept 8 mg was non-inferior to 2 mg for best-corrected visual acuity at 48 weeks. 2. Ocular adverse events ...
Click to read this study in NEJM. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without ...
1. In patients with type 1 diabetes, using intermittently scanned continuous glucose monitoring resulted in significantly lower glycated hemoglobin levels ...
1. An increased incidence of new cardiovascular disease was seen in individuals with autoimmune disease compared to those without. 2. ...
1. Faricimab every 8 weeks and faricimab per personalized treatment interval (PTI) were noninferior to aflibercept for mean change in ...
1. This cross-sectional study discovered that the estimated prevalence of both type 1 and type 2 diabetes among youths in ...
1. Across 3 international registries, 5 similar patterns of hemoglobin A1c (HbA1c) were identified: low stable, intermediate stable, high stable, target ...
1. Time in range after 6 months was higher with rtCGM than with isCGM. 2. Participants on rtCGM scored better ...
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.